Germany’s Cannabis Market Hits EUR 670M: How 900,000 Patients Are Reshaping Europe’s Largest Market

How did Germany become Europe’s largest cannabis market in just two years?

Germany’s cannabis market size hit a milestone that would have seemed impossible as recently as 2022: a medical cannabis segment exceeding EUR 670 million, now serving an estimated 900,000 patients. That explosive growth — driven by landmark legislative reform and telemedicine access — has made Germany not just Europe’s largest cannabis market, but one of the fastest-growing regulated markets in the world.

Understanding Germany cannabis market size matters for every operator eyeing European expansion. The April 2024 Medical Cannabis Act (Medizinal-Cannabis-Gesetz, or MedCanG) removed cannabis from Germany’s narcotics list, eliminated prescription quotas, and opened a wave of telemedicine prescribing that drove cannabis prescriptions up 3,300% in less than two years. What followed was a supply chain scramble, a regulatory tightening, and the clearest signal yet that Germany is Europe’s defining cannabis market for the decade ahead.

This analysis breaks down the EUR 670M figure, who is buying and why, where the supply comes from, and what projections say about the market’s trajectory through 2030.

Germany Cannabis Market Size: EUR 670M and Growing

The EUR 670 million figure comes from Prohibition Partners’ September 2025 analysis of Germany’s medical cannabis segment. This number represents medical cannabis product revenue alone — dried flower, extracts, and derivative forms — sold through German pharmacies. It is the direct result of the MedCanG, which came into force on April 1, 2024.

Before MedCanG, Germany was already Europe’s largest medical cannabis market, but a heavily constrained one. Prescribing required special authorization, quotas limited access, and the supply chain was built around a niche patient population. The new law changed everything: doctors could prescribe cannabis like any other medication, without special permits, and telemedicine platforms immediately began connecting patients with prescribers at scale.

Import volumes tell the story in hard numbers. Germany’s Federal Institute for Drugs and Medical Devices (BfArM) reported that the country imported 56,915 kg of dried cannabis flower in Q3 2025 alone — up 19% from Q2 and 176% year-over-year. In the first nine months of 2025, total imports exceeded 142 tonnes. Germany’s entire 2024 import quota had been 122 tonnes. By October 2025, BfArM raised the national import ceiling by a further 70 tonnes, to 192.5 tonnes.

Cannabis prescriptions surged 3,300% from March 2024 to December 2025, according to InternationalCBC market data. Germany’s medical cannabis market did not simply grow — it reset what “scale” means for a regulated European market.

Who Are Germany’s 900,000 Cannabis Patients?

As of mid-2025, Germany had an estimated 900,000 medical cannabis patients, according to Artemis Growth Partners data cited by cannamonitor.com. That is nearly four times the ~250,000 patients estimated at MedCanG’s April 2024 launch. The growth tracks directly with prescription volumes, which began accelerating the moment the bureaucratic barriers of the old BtMG framework were removed.

Telemedicine Was the Growth Engine

Cannabis-focused telehealth platforms moved quickly after MedCanG. Patients who would not have navigated a traditional GP referral could complete an online consultation and receive a digital prescription — all within hours. In some German states, over 60% of rural patients initially relied solely on telemedicine for cannabis prescriptions, demonstrating how the digital channel reached populations that traditional pharmacy networks had not.

Who Is Seeking Cannabis Therapy?

Chronic pain remains the dominant indication driving Germany’s patient population. Musculoskeletal conditions, neuropathic pain, and general chronic pain syndromes represent the largest share of cannabis prescriptions. Emerging patient segments include people managing endometriosis, cannabis-treatable hormonal sleep disorders, and oncology-related symptoms. As physician awareness grows and clinical evidence accumulates, the indication spectrum is expected to broaden further.

The Telemedicine Restriction and Its Impact

In October 2025, the German Federal Cabinet approved amendments to the MedCanG that tightened telemedicine access: new patients must now have an in-person consultation before receiving a first cannabis prescription, and follow-up telemedicine prescriptions are only valid if the in-person visit occurred within the previous four quarters. The unrestricted “click-to-prescribe” telemedicine model that fuelled 2024’s prescription surge faces structural headwinds entering 2026.

Nevertheless, Germany’s patient base remains far above pre-MedCanG levels. The structural drivers — an aging population, rising physician confidence, and cannabis integration into chronic pain management — provide durable demand that does not depend on easy telemedicine access.

The Supply Chain: Canada, Portugal, and German Domestic Production

Germany’s EUR 670M market runs almost entirely on imports. Domestic production exists but is minimal: only three licensed cannabis producers operate in Germany, two of them subsidiaries of companies headquartered in Canada. Together, domestic facilities supply an estimated less than 3% of national demand. The remaining 97%+ is imported — primarily from Canada and Portugal.

Canada: The Dominant Supplier

In the first three quarters of 2025, Canada supplied 66,237 kg of the 143,307 kg imported into Germany — approximately 46% of total import volume. Canada’s early investment in EU-GMP certification, its established production scale, and its existing trade relationships with German distributors made it the default supplier when MedCanG unlocked demand. Canadian-based operators like Cronos Group, Organigram, Tilray, Canopy Growth, and Aurora Cannabis are active in the German market.

Portugal: Gateway to the German Market

Portugal contributed 42,076 kg (approximately 29%) of Germany’s imports through Q3 2025. Portugal’s role is structurally significant beyond its own production: the country serves as a re-export hub for Canadian and broader European cannabis into Germany and other EU markets. The actual Canadian-origin share of what reaches German pharmacies is likely higher than raw import-origin data suggests.

Supply Diversification Is Accelerating

Together, Canada and Portugal accounted for approximately 77% of German imports in Q3 2025, declining to around 68% in Q4. Supply from Denmark, North Macedonia, and other EU-GMP certified producers is growing. Cannamonitor’s analysis of “The Transatlantic Triangle Under Pressure” notes that Canada and Portugal are straining to keep pace with German demand, making supply diversification a structural requirement rather than a strategic option.

EU-GMP: The Non-Negotiable Compliance Requirement

Every cannabis product sold through a German pharmacy must carry EU-GMP certification from its producing facility. BfArM requires both a general import license and individual shipment-level import permits. Products must meet the standards of the German Pharmacopeia monograph for cannabis flowers (DAB), including Good Agricultural and Collection Practice (GACP) documentation. These requirements create a meaningful barrier to entry but also a durable competitive advantage for certified operators.

What EUR 670M Germany Cannabis Market Size Means for Operators

The EUR 670M figure is not just a headline — it is a signal about where investment, infrastructure, and compliance capacity need to go.

For Canadian producers already exporting to Germany: the market has significant remaining runway. Exporters who secured EU-GMP certification early are capturing share in a segment growing faster than any comparable pharmaceutical product category. The challenge ahead is volume: BfArM has already raised the import ceiling once, and demand growth is projected to continue outpacing original supply estimates.

For operators seeking market entry: EU-GMP certification is the critical gating factor. The certification process for cannabis facilities typically requires 12 to 24 months from initial gap assessment to approval. Companies that have not started this process face a meaningful delay before they can legally access Germany’s market. Early movers hold a structural advantage that compounds over time.

For domestic German operators: three licensed producers covering less than 3% of demand at a EUR 670M market represents one of the clearest market gaps in European cannabis. Operators building in-country facilities face dual compliance requirements — GACP plus EU-GMP — but stand to benefit from proximity advantages, local regulatory relationships, and logistics efficiency as demand scales.

For all operators: track-and-trace infrastructure is not optional. Germany’s regulatory environment requires shipment-specific import permits, auditable batch records, and chain of custody documentation that supports pharmacovigilance. Cannabis compliance software built to EU-GMP standards — covering cultivation records, batch documentation, quality assurance workflows, and regulatory reporting — provides the operational infrastructure to scale inside Germany’s framework. Companies operating manual or spreadsheet-based systems face both audit risk and operational bottlenecks as volumes grow.

Projections: Where the Germany Cannabis Market Size Is Heading

The EUR 670M figure captures 2025 medical cannabis revenue, but multiple independent forecast frameworks project substantially larger numbers ahead.

Several structural factors support the upper end of these projections:

Patient Penetration Has Room to Run

At 900,000 patients in a country of 84 million people, Germany’s medical cannabis penetration rate sits below 1.1% of the total population. Mature medical cannabis markets — Canada, Israel, Australia — have reached 3–5% of the adult population. If Germany reaches even 2% adult penetration, the patient count would exceed 1.3 million. Each incremental patient means more prescriptions, more pharmacy orders, more import volume.

Physician Confidence Is Compounding

Post-MedCanG prescribing data shows that doctor willingness to prescribe cannabis is increasing, not decreasing. As clinical evidence accumulates and medical education programs incorporate cannabis pharmacology, the prescribing rate is expected to continue rising independent of telemedicine access. The Cansativa Group’s 2026 outlook specifically cited “increasing prescribing confidence among physicians” as a primary growth driver.

Pillar 2 Commercial Pilots Could Reset Projections

Germany’s cannabis reform law includes a second pillar enabling commercial adult-use cannabis pilots in select regions. The government has committed to reviewing pilot program data in late 2026, with potential nationwide retail expansion potentially following in 2027. If Pillar 2 proceeds on schedule, Germany cannabis market size forecasts could be reset dramatically upward — adding an entirely new consumer segment on top of the established medical market.

Import Infrastructure Is Scaling

BfArM’s willingness to raise import ceilings — from 122 to 192.5 tonnes in a single revision — signals that regulatory capacity will follow demand rather than constrain it. Germany’s market is not supply-limited in a regulatory sense; it is compliance-certified-supply-limited. As more global producers achieve EU-GMP certification, supply constraints will ease and competition will increase.

For operators building European strategy now, the window of competitive advantage is open — but not indefinitely. Germany cannabis market size is large enough to support multiple significant players, but EU-GMP certification, compliance infrastructure, and distribution relationships take time to build. Companies that delay entry face a market that will be far more crowded when they eventually arrive.

Frequently Asked Questions

Supplying Germany’s EUR 670M Cannabis Market?

GrowerIQ’s EU-GMP compliant platform helps producers meet Germany’s strict import and quality requirements — from batch records and GACP documentation to full seed-to-sale traceability.

REQUEST DEMO